SAN DIEGO–(BUSINESS WIRE)–Avenzo to Present Initial Results from Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at San Antonio Breast Cancer Symposium
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
